Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1165-1173

  Bannister, C A ^a   Holden, S E ^a,b   Jenkins Jones, S ^b   Morgan, C Ll ^b   Halcox, J P ^c   Schernthaner, G ^d   Mukherjee, J ^e   Currie, C J ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Global Epidemiology   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

All cause mortality; Metformin; Sulphonylurea; Type 2 diabetes

Indexed keywords

METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; CHEMICALLY INDUCED; COMPARATIVE STUDY; CONTRAINDICATIONS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; STROKE; UNITED KINGDOM;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; SULFONYLUREA COMPOUNDS;

EID: 84914165449     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12354     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet 2011. Available from URL: http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed 28 January 2014.
2. Diabetes UK. Diabetes in the UK 2012: Key statistics on diabetes 2012. Available from URL: http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2012.pdf. Accessed 18 December 2013.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Holden SE, Currie CJ. Mortality risk with sulphonylureas compared to metformin. Diabetes Obes Metab 2014; DOI: 10.1111/dom.12280 [Epub ahead of print].
5. Massó González EL, Johansson S, Wallander MA, García Rodríguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009; 63: 332-336.
6. Turner LW, Nartey D, Stafford RS, Singh S, Caleb Alexander G. Ambulatory treatment of type 2 diabetes mellitus in the United States, 1997-2012. Diabetes Care 2014; 37: 985-992.
7. U.S. Food and Drug Administration. Drugs @FDA. Drug Details-Glucophage. Silver Spring: U.S. Food and Drug Administration 2014. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=GLUCOPHAGE. Accessed 8 March 2014.
8. Morgan CLl, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 4605-4612.
9. Pantalone KM, Kattan MW, Yu C et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 2012; 14: 803-809.
10. Forst T, Hanefeld M, Jacob S et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013; 10: 302-314.
11. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552-1561.
12. Morgan CLl, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab 2014; DOI: 10.1111/dom.12302 [Epub ahead of print].
13. Sturgess NC. The sulfonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985; 326: 474-475.
14. Terzic A, Jahangir A, Kurachi Y. Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Am J Physiol 1995; 269: C525-545.
15. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
16. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202.
17. Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-625.
18. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
19. Franciosi M, Lucisano G, Lapice E, Strippoli GFM, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583.
20. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
21. Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157: 601-610.
22. Clinical Practice Research Datalink (CPRD). Clinical Practice Research Datalink. 2013. Available from URL: http://www.cprd.com/intro.asp. Accessed 17 June 2013.
23. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 87: 36-40.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
25. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Stat 1999; 48: 313-329.
26. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. 2nd edn. New York: Springer, 2006.
27. The R Project for Statistical Computing. Available from URL: http://www.r-project.org. Accessed 3 February 2014.
28. Morgan CLl, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014; DOI: 10.1111/dom.12306 [Epub ahead of print].
29. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-502.
30. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
31. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
32. Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 2010; 19: 335-342.
33. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin inx type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900-1908.
34. Hong J, Zhang Y, Lai S et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36: 1304-1311.
35. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 349-357.
36. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012; 2012: 413782.
37. Ruiter R, Visser LE, van Herk-Sukel MP et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012; 35: 119-124.
38. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010; 53: 1631-1637.
39. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011; 13: 221-228.
40. Stevens RJ, Ali R, Bankhead CR et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55: 2593-2603.
41. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128-136.
42. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819.